Bryan Lin

Bryan Lin currently serves as Associate Director of Strategic Market Insights for Hemophilia and PKU at BioMarin Pharmaceutical Inc., a position held since May 2023. Prior to this role, Bryan was an Associate Principal at IPM.ai, focusing on machine learning-powered patient insights for rare disease and oncology clients from January 2021 to May 2023. Between March 2018 and January 2021, Bryan worked as Principal at Adivo Associates LLC, leading market sizing and financial modeling initiatives in rare diseases, while also managing business development. Earlier experience includes positions in healthcare consulting and as a CEO/co-founder of Vessel Science. Bryan began a career in research as a Research Associate at NVIGEN and holds a BA in Chemistry with a concentration in Biochemistry from Washington University in St. Louis.